Aktis Oncology, Inc. (AKTS)
Nasdaq: AKTS · Pharmaceutical Preparations · filing with the SEC since 2024
Who owns Aktis Oncology, Inc.
As filed with the SECHolders of 5% or more
5
Ansbert Gadicke holds 19.3% of Common Stock, as its SCHEDULE 13D filed Jan 20, 2026 says.
Directors and officers
14
report now, of 14 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Ansbert Gadicke
SCHEDULE 13D · filed Jan 20, 2026 · Common Stock
Eli Lilly & Co.
SCHEDULE 13D · filed Jan 15, 2026 · Common Stock, $0.0001 par value per share
VV Manager II LLC
SCHEDULE 13D · filed Jan 14, 2026 · Common Stock, $0.0001 par value per share
EcoR1 Capital, LLC
SCHEDULE 13D · filed Jan 20, 2026 · Common Stock
Blue Owl Capital Holdings LP
SCHEDULE 13G · filed May 14, 2026 · Common Stock, par value $0.0001 per share
What AKTS reports owning in othersstakes of 5% or more, and other ties
Aktis Oncology, Inc. reports no stake in another company in the record.
Insider tradesForm 4
11sales
5purchases
2sales on a scheduled plan
3people selling
$3.2Msold, in dollars
$59.2Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Czibere Akos | Chief Medical Officer | 5 | $1.6M | 2 | 0 | $0 |
| Ron-Bigger Shulamit | Chief Operating Officer | 3 | $1.4M | 0 | 0 | $0 |
| Herrmann Ken | director | 3 | $200,000 | 0 | 0 | $0 |
| Kim Helen Susan | director | 0 | $0 | 0 | 2 | $15.0M |
| Nodelman Oleg | director | 0 | $0 | 0 | 2 | $40.0M |
| Vida Ventures II-A, LLC | 10% owner | 0 | $0 | 0 | 2 | $15.0M |
| Foley Todd | director | 0 | $0 | 0 | 1 | $4.2M |
| Gadicke Ansbert | 10% owner | 0 | $0 | 0 | 1 | $20.0M |
| Mpm Oncology Innovations Fund LP | 10% owner | 0 | $0 | 0 | 1 | $20.0M |